medigraphic.com
ISSN 0035-0052 (Print)

2021, Number 1

<< Back

Rev Mex Pediatr 2021; 88 (1)

Update on clinical management of COVID-19 in pediatric patients: after a year of pandemic

Montaño-Luna VE, Miranda-Novales MG

Language: Spanish
References: 65
Page: 31-45
PDF size: 361.55 Kb.


ABSTRACT

On December 2019, a new virus was announced as the cause of an outbreak of severe pneumonia in China. WHO declared the SARS-CoV-2 pandemic due to the rising cases worldwide On March 11th 2020. The incubation period ranges from 1-12.5 days (average 5-6 days) and its transmission is by droplets, and direct contact, with an unclear transmission during aerosol-generating procedures in the community setting. In almost all pediatric cases, a household contact is the source of infection, and most of these patients are asymptomatic and have a mild respiratory condition. However, few patients develop severe manifestations such as pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) which consists in a wide spectrum of clinical manifestations with hyperinflammatory symptoms that include prolonged fever, hypovolemia and shock that may lead to death. Unfortunately, there is no specific treatment approved for use in pediatric patients, despite the time that has passed and multiple different research studies have been conducted. For this reason, management must continue to be based on supportive treatment and timely case identification. This document aims to guide the management of pediatric patients suspected or confirmed of COVID-19, according to the findings of research studies conducted through January 2021.


REFERENCES

  1. Aragón-Nogales R, Vargas-Almanza I, Miranda-Novales MG. COVID-19 por SARS-CoV-2: la nueva emergencia de salud. Rev Mex Pediatr. 2019; 86(6): 213-218. https://dx.doi.org/10.35366/91871

  2. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17(3): 181-192. doi: 10.1038/s41579-018-0118-9.

  3. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019; 16(1): 69. doi: 10.1186/s12985-019-1182-0.

  4. Arif TB. The 501.V2 and B.1.1.7 variants of coronavirus disease 2019 (COVID-19): a new time-bomb in the making? Infect Control Hosp Epidemiol. 2021; 1-2. doi: 10.1017/ice.2020.1434. Epub ahead of print.

  5. Montaño-Luna VE, Pacheco-Rosas DO, Vázquez-Rosales JG, Labra-Zamora MG, Fuentes-Pacheco Y, Sámano-Aviña M et al. Manejo clínico de casos pediátricos de COVID-19. Rev Med IMSS. 2020. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/3702/3736

  6. Cheng VCC, Wong SC, Chen JHK, Yip CCY, Chuang VWM, Tsang OTY et al. Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. Infect Control Hosp Epidemiol. 2020; 41(5): 493-498. doi: 10.1017/ice.2020.58.

  7. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). Appendices. [Fecha de acceso 4 de enero 2021] Available in: https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/appendix.html#contact

  8. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020; 172(9): 577-582. doi: 10.7326/M20-0504.

  9. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021; 4(1): e2035057. doi: 10.1001/jamanetworkopen.2020.35057.

  10. WHO Coronavirus disease 2019 (COVID-19). Weekly epidemiological update-12 January 2021. [Fecha de acceso 12 de enero de 2021] Available in: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

  11. Comunicado Técnico diario. Nuevo Coronavirus en el mundo (COVID-19). Secretaría de Salud. [Fecha de acceso 15 de enero de 2021] Disponible en: https://www.gob.mx/cms/uploads/attachment/file/606686/Comunicado_Tecnico_Diario_COVID-19_2021.01.15.pdf

  12. Secretaría de Salud. Documentos. Datos abiertos bases históricas. Disponible en: https://www.gob.mx/salud/documentos/datos-abiertos-bases-historicas-direccion-general-de-epidemiologia

  13. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020; 323(14): 1335. doi: 10.1001/jama.2020.4344.

  14. Tagarro A, Epalza C, Santos M, Sanz-Santaeufemia FJ, Otheo E, Moraleda C et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020; e201346. doi: 10.1001/jamapediatrics.2020.1346.

  15. Williams PCM, Howard-Jones AR, Hsu P, Palasanthiran P, Gray PE, McMullan BJ et al. SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology. 2020; 52(7): 801-808. doi: 10.1016/j.pathol.2020.08.001.

  16. Cai J, Xu J, Lin D, Yang z, Xu L, Qu Z et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020; 71(6): 1547-1551. doi: 10.1093/cid/ciaa198.

  17. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020; 145(6): e20200702. doi: 10.1542/peds.2020-0702.

  18. Lu X, Zhang L, Du H, Zhang J, Li YY, Zhang W et al. SARS-CoV-2 infection in children. N Engl J Med. 2020; 382(17): 1663-1665. doi: 10.1056/NEJMc2005073.

  19. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109(6): 1088-1095. doi: 10.1111/apa.15270.

  20. Kimberlin DW, Stagno S. Can SARS-CoV-2 infection be acquired in utero? More definitive evidence is needed. JAMA. 2020; 323(18): 1788-1789. doi: 10.1001/jama.2020.4868.

  21. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020; 395(10226): 809-815. doi: 10.1016/S0140-6736(20)30360-3. Epub 2020 Feb 12. Erratum in: Lancet. 2020; 395(10229): 1038.

  22. Boulad F, Kamboj M, Bouvier N, Mauguen A, Kung AL. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020; 6(9): 1459-1460. doi: 10.1001/jamaoncol.2020.2028.

  23. Balduzzi A, Brivio E, Rovelli A, Rizzari C, Gasperini S, Melzi ML et al. Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone Marrow Transplant. 2020; 55(10): 1900-1905. doi: 10.1038/s41409-020-0895-4.

  24. López-Aguilar E, Cárdenas-Navarrete R, Simental-Toba A, Pacheco-Rosas D, Thomé-Ortiz P, Soto-Pérez G et al. Children with cancer during COVID-19 pandemic: early experience in Mexico. Pediatr Blood Cancer. 2021; 68(2): e28660. doi: 10.1002/pbc.28660.

  25. Dirección General de Epidemiología. Lineamiento estandarizado para la vigilancia epidemiológica y por laboratorio de la enfermedad respiratoria viral. Diciembre de 2020. [Fecha de acceso 4 de enero del 2021] Disponible en: https://coronavirus.gob.mx/wp-content/uploads/2020/04/Lineamiento_de_vigilancia_epidemiologica_de_enfermedad_respiratoria-_viral.pdf

  26. Asociación Española de Pediatría. Documento de manejo clínico del paciente pediátrico con infección por SARS-CoV-2. Noviembre, 2020. [Fecha de acceso 8 de enero de 2021] Disponible en: https://www.aeped.es/sites/default/files/b26-11-_aep-seip-secip-seup._documento_de_manejo_clinico_del_paciente_pediatrico.pdf

  27. Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C et al. Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer. 2020; 132: 11-16. doi: 10.1016/j.ejca.2020.03.021.

  28. André N, Rouger-Gaudichon J, Brethon B, Phulpin A, Thébault E, Pertuisel S et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: high risk of severe forms? Pediatr Blood Cancer. 2020; 67(7): e28392. doi: 10.1002/pbc.28392.

  29. de Rojas T, Pérez-Martínez A, Cela E, Baragaño M, Galán V, Mata C et al. COVID-19 infection in children and adolescents with cancer in Madrid. Pediatr Blood Cancer. 2020; 67(7): e28397. doi: 10.1002/pbc.28397.

  30. Sullivan M, Bouffet E, Rodriguez-Galindo C, Luna-Fineman S, Khan MS, Kearns P et al. The COVID-19 pandemic: a rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. Pediatr Blood Cancer. 2020; 67(7): e28409. doi: 10.1002/pbc.28409.

  31. National Comprehensive Cancer Network. Infectious disease management and considerations in cancer patients with documented or suspected COVID-19. 2020. [Fecha de acceso 9 de enero del 2021] Disponible en: https://www.nccn.org/COVID-19/pdf/ COVID_Infections.pdf.

  32. Foust AM, McAdam AJ, Chu WC, Garcia-Peña P, Phillips GS, Plut D et al. Practical guide for pediatric pulmonologists on imaging management of pediatric patients with COVID-19. Pediatr Pulmonol. 2020; 55(9): 2213-2224. doi: 10.1002/ppul.24870.

  33. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020; 323(22): 2249-2251. doi: 10.1001/jama.2020.8259.

  34. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F et al. Early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020; 71(15): 778-785. doi: 10.1093/cid/ciaa310.

  35. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available in: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf

  36. Soma VL, Shust GF, Ratner AJ. Multisystem inflammatory syndrome in children. Curr Opin Pediatr. 2021; 33(1): 152-158. doi: 10.1097/MOP.0000000000000974.

  37. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020; 324(3): 259-269. doi: 10.1001/jama.2020.10369.

  38. Kaushik S, Aydin SI, Derespina KR, Bansal PB, Kowalsky S, Trachtman R et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multi-institutional study from New York City. J Pediatr. 2020; 224: 24-29. doi: 10.1016/j.jpeds.2020.06.045.

  39. Dulek DE, Fuhlbrigge RC, Tribble AC, Connelly JA, Loi MM, El Chebib H et al. Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute COVID-19 in pediatric patients. J Pediatric Infect Dis Soc. 2020; piaa098. doi: 10.1093/jpids/piaa098.

  40. Nijman RG, De Guchtenaere A, Koletzko B, Ross Russell R, Copley S, Titomanlio L et al. Pediatric inflammatory multisystem syndrome: statement by the pediatric section of the European Society for Emergency Medicine and European Academy of Pediatrics. Front Pediatr. 2020; 8: 490. doi: 10.3389/fped.2020.00490.

  41. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020; 383(19): 1813-1826. doi: 10.1056/NEJMoa2007764.

  42. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020; 324(11): 1048-1057.

  43. Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014; 30(9): 445-455. doi: 10.1016/j.pt.2014.07.005.

  44. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178: 104787. doi: 10.1016/j.antiviral.2020.104787.

  45. Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020; 102(6): 1156-1157. doi: 10.4269/ajtmh.20-0271.

  46. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002; 42(10): 1122-1133. doi: 10.1177/009127002401382731.

  47. Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P et al. Prioritization of anti-SARS-CoV-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020; 108(4): 775-790. doi: 10.1002/cpt.1909.

  48. The COVID-19 Treatment Guidelines. Panel's statement on the use of ivermectin for the treatment of COVID-19. [Fecha de acceso enero 19, 2021] Available in: https://www.Covid19treatmentguidelines.nih.gov/statement-on-ivermectin/

  49. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-271. doi: 10.1038/s41422-020-0282-0.

  50. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2: 69. doi: 10.1186/1743-422X-2-69.

  51. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020; 383(21): 2030-2040. doi: 10.1056/NEJMoa2022926.

  52. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM et al. Hydroxychloroquine in non-hospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020; 173(8): 623-631. doi: 10.7326/M20-4207.

  53. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020; 382(19): 1787-1799. doi: 10.1056/NEJMoa2001282.

  54. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020; NEJMoa2021436. doi: 10.1056/NEJMoa2021436.

  55. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005; 44(1): 61-98. doi: 10.2165/00003088-200544010-00003.

  56. Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin Transl Immunology. 2020; 9(10): e1192. doi: 10.1002/cti2.1192.

  57. Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J et al. Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. Clin Infect Dis. 2020; ciaa721. doi: 10.1093/cid/ciaa721.

  58. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. 2020; 2020.08.12.20169359. doi: 10.1101/2020.08.12.20169359.

  59. Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol. 2009; 83(7): 3039-3048. doi: 10.1128/JVI.01792-08.

  60. Xu X, Han M, Li T, Sun W, Wang D, Fu B et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20): 10970-10975. doi: 10.1073/pnas.2005615117.

  61. Sciascia S, Apra F, Baffa A, Baldovino S, Boaro D, Boero R et al Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020; 38(3): 529-532.

  62. Loi M, Branchford B, Kim J, Self C, Nuss R. COVID-19 anticoagulation recommendations in children. Pediatr Blood Cancer. 2020; 67(9): e28485. doi: 10.1002/pbc.28485.

  63. Goldenberg NA, Sochet A, Albisetti M, Biss T, Bonduel M, Jaffray J et al. Pediatric/neonatal hemostasis and thrombosis subcommittee of the ISTH SSC. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020; 18(11): 3099-3105. doi: 10.1111/jth.15073.

  64. World Health Organization. Transmission of SARS-CoV-2 implications for infection prevention precautions. 2020. [Fecha de acceso 12 de enero del 2021] Available in: https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-COVID-19-implications-for-ipc-precaution-recommendations.

  65. World Health Organization. Advice on the use of masks in the context of COVID-19. 2020. [Fecha de acceso 12 de enero del 2021] Available in: https://apps.who.int/iris/bitstream/handle/10665/332293/WHO-2019-nCov-IPC_Masks-2020.4-eng.pdf?sequence=1&isAllowed=y




2020     |     www.medigraphic.com